Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results [Yahoo! Finance]
Inhibrx Biosciences, Inc. (INBX)
Company Research
Source: Yahoo! Finance
Following the completion of the sale of INBRX-101 (the "101 Transaction") by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. (the "Acquirer") and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials. Inhibrx, Inc. logo (PRNewsfoto/Inhibrx, Inc.) Upcoming Milestones ozekibart (INBRX-109) We expect to submit the Biologics License Application ("BLA") for ozekibart for the treatment of unresectable or metastatic conventional chondrosarcoma to the U.S. Food and Drug Administration ("FDA") early in the second quarter of 2026; We plan to announce progression-free survival ("PFS") data for the Phase 1/2 colorectal cancer expansion cohort in the second quarter of 2026; and We plan to meet with the FDA to discuss accelerated approval for Ewing Sarcoma and fourth line colorectal cancer in the second half of 2026. INBRX-106 We plan to announce interim objective response rate ("
Show less
Read more
Impact Snapshot
Event Time:
INBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INBX alerts
High impacting Inhibrx Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
INBX
News
- Inhibrx Biosciences GAAP EPS of -$2.11 misses by $0.03 [Seeking Alpha]Seeking Alpha
- Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial ResultsPR Newswire
- Inhibrx Announces Participation in Upcoming Scientific Conference [Yahoo! Finance]Yahoo! Finance
- Inhibrx Announces Participation in Upcoming Scientific ConferencePR Newswire
- Chondrosarcoma Treatment Market Forecasts Robust Growth During the Forecast Period (2026-2036) as Oncology Pipeline Strengthens | DelveInsight [Yahoo! Finance]Yahoo! Finance
INBX
Earnings
- 8/13/25 - Beat
INBX
Sec Filings
- 3/19/26 - Form 10-K
- 3/19/26 - Form 8-K
- 2/23/26 - Form 8-K
- INBX's page on the SEC website